Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18313915 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | CRAIG, KAILA ANGELIQUE | 61d |
| 18985740 | COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENT | BAEK, BONG-SOOK | — |
| 18541289 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | BORALSKY, LUKE ALAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18313915 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | CRAIG, KAILA ANGELIQUE | 61d |
| 18985740 | COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENT | BAEK, BONG-SOOK | — |
| 18762266 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | WELLS, LAUREN QUINLAN | — |
| 18587187 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | MCDOWELL, BRIAN E | — |
| 18541289 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | BORALSKY, LUKE ALAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1629 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18985740 | COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENT | BAEK, BONG-SOOK | 1629 | §101§103Other | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18762266 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | WELLS, LAUREN QUINLAN | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18587187 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | MCDOWELL, BRIAN E | 1624 | §102Other | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18541289 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | BORALSKY, LUKE ALAN | 1624 | §101§102§112Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18313915 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | CRAIG, KAILA ANGELIQUE | 1618 | §103§112 | Non-Final OA | 61d | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial